SummitTX Capital L.P. Purchases Shares of 28,722 Pfizer Inc. $PFE

SummitTX Capital L.P. acquired a new position in Pfizer Inc. (NYSE:PFE) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 28,722 shares of the biopharmaceutical company’s stock, valued at approximately $807,000.

Several other institutional investors and hedge funds have also recently modified their holdings of PFE. Norges Bank purchased a new stake in Pfizer in the 4th quarter worth $1,830,986,000. Morgan Stanley lifted its position in shares of Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after acquiring an additional 14,342,946 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Pfizer by 38.9% in the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after acquiring an additional 13,581,757 shares during the period. Janus Henderson Group PLC grew its position in shares of Pfizer by 577.5% during the fourth quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock worth $218,817,000 after purchasing an additional 7,489,189 shares in the last quarter. Finally, Capital World Investors grew its position in shares of Pfizer by 51.5% during the fourth quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company’s stock worth $533,704,000 after purchasing an additional 7,287,194 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on PFE. Citigroup boosted their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a report on Tuesday, June 9th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.50.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.92 on Friday. The firm has a market cap of $142.04 billion, a PE ratio of 19.02 and a beta of 0.35. The stock has a 50 day moving average of $25.06 and a 200 day moving average of $26.16. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio is presently 131.30%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Encouraging vitiligo data could strengthen Pfizer’s growth pipeline. Two Phase 3 trials showed that LITFULO significantly improved skin repigmentation in patients with nonsegmental vitiligo. Pfizer plans global regulatory submissions, potentially expanding the drug beyond its existing uses and creating a new commercial opportunity. Pfizer’s oral drug restores skin pigmentation in late-stage vitiligo trials
• Positive Sentiment: EU authorization for the updated COVID-19 vaccine supports the 2026–2027 season. The European Commission approved Pfizer and BioNTech’s XFG-adapted Comirnaty vaccine for people six months and older across the European Union. The decision allows manufacturing and supply preparations, although the mature and seasonal COVID market may limit the financial upside. Pfizer Wins EU Approval For Updated COVID Vaccine Ahead Of 2026 Season
• Positive Sentiment: Pfizer continues to build its oncology pipeline. The company is advancing the Phase 2 Symbiotic-Lung-10 trial, offering potential long-term upside if the lung-cancer program produces favorable results. However, Phase 2 development means any revenue contribution remains several years away. Pfizer’s Symbiotic-Lung-10 Trial
• Neutral Sentiment: Investors are focused on the upcoming second-quarter report. Preview reports highlight expectations for key products, COVID-related headwinds, and possible updates to full-year guidance. Pfizer’s latest quarter exceeded estimates, but earnings declined year over year, leaving results and management commentary as the near-term catalysts. Pfizer Q2 Earnings Preview
• Positive Sentiment: Additional vaccine demand may support established products. Québec selected Pfizer’s Prevnar 20 for its publicly funded pediatric pneumococcal immunization program, providing a potential boost to vaccine sales and market presence. Pfizer’s PREVNAR 20 Selected for Québec Program

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.